MA43020A - Nouveaux dérivés d'imidazo[4,5-b]pyridine utilisés comme inhibiteurs de dyrk1/clk1 doubles - Google Patents

Nouveaux dérivés d'imidazo[4,5-b]pyridine utilisés comme inhibiteurs de dyrk1/clk1 doubles

Info

Publication number
MA43020A
MA43020A MA043020A MA43020A MA43020A MA 43020 A MA43020 A MA 43020A MA 043020 A MA043020 A MA 043020A MA 43020 A MA43020 A MA 43020A MA 43020 A MA43020 A MA 43020A
Authority
MA
Morocco
Prior art keywords
dyrk1
imidazo
double
new derivatives
pyridine used
Prior art date
Application number
MA043020A
Other languages
English (en)
Inventor
Michaël Frank Burbridge
Balázs Bálint
Francisco Humberto Cruzalegui
Nicolas Foloppe
András Kotschy
Melinda Sipos
David Walmsley
Csaba Wéber
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of MA43020A publication Critical patent/MA43020A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
MA043020A 2015-09-30 2016-09-30 Nouveaux dérivés d'imidazo[4,5-b]pyridine utilisés comme inhibiteurs de dyrk1/clk1 doubles MA43020A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1559252A FR3041639B1 (fr) 2015-09-30 2015-09-30 NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT

Publications (1)

Publication Number Publication Date
MA43020A true MA43020A (fr) 2018-08-08

Family

ID=54979755

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043020A MA43020A (fr) 2015-09-30 2016-09-30 Nouveaux dérivés d'imidazo[4,5-b]pyridine utilisés comme inhibiteurs de dyrk1/clk1 doubles

Country Status (26)

Country Link
US (1) US20180273528A1 (fr)
EP (1) EP3356363A1 (fr)
JP (1) JP2018535931A (fr)
KR (1) KR20180054858A (fr)
CN (1) CN108137581A (fr)
AU (1) AU2016333505A1 (fr)
BR (1) BR112018006157A2 (fr)
CA (1) CA2999935A1 (fr)
CL (1) CL2018000783A1 (fr)
CO (1) CO2018003473A2 (fr)
CR (1) CR20180181A (fr)
CU (1) CU20180028A7 (fr)
DO (1) DOP2018000083A (fr)
EA (1) EA201890821A1 (fr)
EC (1) ECSP18023253A (fr)
FR (1) FR3041639B1 (fr)
HK (1) HK1255804A1 (fr)
IL (1) IL258341A (fr)
MA (1) MA43020A (fr)
MX (1) MX2018003860A (fr)
NI (1) NI201800043A (fr)
PE (1) PE20181331A1 (fr)
PH (1) PH12018500650A1 (fr)
SV (1) SV2018005657A (fr)
TN (1) TN2018000090A1 (fr)
WO (1) WO2017055530A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12528810B2 (en) 2018-03-01 2026-01-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK/CLK and uses thereof
CN108822103A (zh) * 2018-07-28 2018-11-16 刘凤娟 一种咪唑并[4,5-b]吡啶化合物及其制备方法和应用
EP3856186A4 (fr) * 2018-09-28 2022-07-06 Arizona Board of Regents on behalf of the University of Arizona Inhibiteurs à petites molécules de dyrk1/clk et leurs utilisations
EP3873608A1 (fr) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Composés 6-azabenzimidazole substitués ayant une activité inhibitrice de hpk1
EP4371987B9 (fr) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Composés de 6-azabenzimidazole substitués utilisés en tant qu'inhibiteurs de hpk1
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
AU2020345950A1 (en) * 2019-09-11 2022-03-31 Prelude Therapeutics Incorporated CDK inhibitors and their use as pharmaceuticals
CA3195150A1 (fr) 2020-10-08 2022-04-14 Sven Weiler Derives de benzo[h]quinazolin-4-amine et de thieno[3,2-h]quinazolin-4-amine pour le traitement du cancer
WO2026024933A1 (fr) * 2024-07-24 2026-01-29 Prelude Therapeutics Incorporated Inhibiteurs de cdk et leur utilisation en tant que produits pharmaceutiques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201444820A (zh) * 2013-03-13 2014-12-01 Abbvie Inc 吡啶ｃｄｋ９激酶抑制劑

Also Published As

Publication number Publication date
KR20180054858A (ko) 2018-05-24
SV2018005657A (es) 2018-07-31
ECSP18023253A (es) 2018-04-30
CR20180181A (es) 2018-06-22
EA201890821A1 (ru) 2018-10-31
HK1255804A1 (zh) 2019-08-23
CA2999935A1 (fr) 2017-04-06
CN108137581A (zh) 2018-06-08
JP2018535931A (ja) 2018-12-06
CL2018000783A1 (es) 2018-09-21
PE20181331A1 (es) 2018-08-20
TN2018000090A1 (en) 2019-07-08
WO2017055530A1 (fr) 2017-04-06
AU2016333505A1 (en) 2018-04-19
BR112018006157A2 (pt) 2018-10-09
US20180273528A1 (en) 2018-09-27
NI201800043A (es) 2018-06-21
PH12018500650A1 (en) 2018-10-01
FR3041639B1 (fr) 2019-01-25
MX2018003860A (es) 2018-08-16
CU20180028A7 (es) 2018-07-05
EP3356363A1 (fr) 2018-08-08
IL258341A (en) 2018-05-31
CO2018003473A2 (es) 2018-07-10
DOP2018000083A (es) 2018-10-15
FR3041639A1 (fr) 2017-03-31

Similar Documents

Publication Publication Date Title
MA43021A (fr) Nouveaux dérivés pyrrolo [2,3-d]pyrimidine utilisés en tant qu'inhibiteurs doubles de dyrk1/clk1
LT3790877T (lt) Tetrahidro-imidazo[4,5-c]piridino dariniai kaip pd-l1 imunomoduliatoriai
DK3712152T3 (da) 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus kinase-inhibitorer
DK3371185T3 (da) 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus-kinase-inhibitorer
EA201791692A1 (ru) 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ
IL256898A (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
DK3466955T3 (da) Fremgangsmåde til fremstilling af oxazol[4,5-b]pyridin og thiazol[4,5-b]pyridinderivater som irak4-hæmmere til behandling af cancer
LT3555097T (lt) Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai
MA41251A (fr) Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk
DK3489238T3 (da) Farmaceutiske sammensætninger af 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-on- og [1,2,4]triazolo[1,5-c]pteridin-5(6h)-on-derivater som pde1-inhibitorer til behandling af for eksempel neurologiske lidelser
MA43753A (fr) Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu
DK3324977T3 (da) Benzodiazepinderivater som rsv-inhibitorer
KR102161364B9 (ko) LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체
DK3478681T3 (da) 1h-pyrazolo[4,3-b]pyridiner som pde1-inhibitorer
DK2922828T3 (da) 4,6-diamino-pyrimidin-derivater som bmi-1-inhibitorer til at behandle cancer
EA201491376A1 (ru) Производные 1h-пирроло[2,3-b]пиридина и их применение в качестве ингибиторов киназы
EA201400182A1 (ru) Производные пиридин-2(1н)-она в качестве ингибиторов jak
EP3337787A4 (fr) Composés pyrazolo hétérocycliques condensés comme inhibiteurs d'erk
IL258341A (en) New imidazo[4,5-b]pyridine derivatives as dual dyrk1/clk1 inhibitors
DK3194388T3 (da) Imidazo[4,5-c]pyridin afledte ssao-inhibitorer
EP3380475A4 (fr) Dérivés d'octahydropyrrolo [3, 4-c
DK2861608T3 (da) Prodrug-derivater af (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamid
IL269214B (en) Novel imidazo[5,4-c]quinoline derivatives as lrrk2 inhibitors
ZA201705933B (en) 2-phenyl-3h-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity
ZA201701214B (en) Imidazo[1,2-a]pyridine derivatives for use as inhibitors of human immunodeficiency virus replication